Redifferentiating agents in non-radioiodine avid cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 5, 2009, Pages 513-519

  Seregni, E ^a   Vellani, C ^a   Castellani, M R ^a   Maccauro, M ^a   Pallotti, F ^a   Scaramellini, G ^a   Guzzo, M ^a   Greco, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Endocrine system; Radiotherapy; Thyroid neoplasms

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALITRETINOIN; ARSENIC TRIOXIDE; AZACITIDINE; BEXAROTENE; CIGLITAZONE; DEPSIPEPTIDE; FLUORODEOXYGLUCOSE F 18; HISTONE DEACETYLASE INHIBITOR; IODINE 131; ISOTRETINOIN; RADIOACTIVE IODINE; RETINAL; RETINOIC ACID; RETINOID; RETINOL; ROMIDEPSIN; ROSIGLITAZONE; TAZAROTENE; THYROID HORMONE; TRICHOSTATIN A; TROGLITAZONE; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CELL METABOLISM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG UPTAKE; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; THYROID CANCER; THYROID CELL; THYROID HORMONE BLOOD LEVEL; TREATMENT INDICATION; TUMOR DIFFERENTIATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; HUMANS; IODINE RADIOISOTOPES; THYROID NEOPLASMS;

EID: 76349084717     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83-95.
2. Shimaoka K, Schoenfeld DA, De Wys WD, Creech RH, De Conti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.
3. Bizhanova A, Kopp P. Minireview: The Sodium-Iodine Symporter NIS and Pendrin in Iodine Homeostasis of the thyroid. Endocr 2009;150:1084-90.
4. Bollag W. New retinoids with potential use in human. In: J. H. Saurat, editor. Retinoids: new trends in research and therapy. Bassel: Karger AG; 1985. p. 274-88.
5. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM et al. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000;21:1271-9.
6. Rastinejad F. Retinoid X receptor an its partners in the nuclear receptor family. Curr Opin Struct Biol 2001;11:33-8.
7. Kogai T, Ohashi E, Jacobs SM, Sajid-Crockett S, Fisher ML, Kanamoto Y et al. Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is meditated by the insulin growth factoi/ phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways. J Clin Endocrinol Metab 2008;93:1884-92.
8. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002;29:775-82.
9. Grüning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG et al. Retinoic acid for redifferentiation ojf thyroid cancer-does it hold its promise? Eur J Endocrinol 2003;148:395-402.
10. Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB et al. Redifferentiation therapy with 13-cis Retinoic Acids in radioiodine-resistant thyroid cancer. Endocrine Journal 2009;56:105-12.
11. Short SC, Suovuori A, Cook G, Vivian G, Harmer C. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol 2004;16:569-74.
12. Grunwald F, Menzel C, Bender H, Palmedo H, Rolf O, Fimmers R et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998;11;1903-6.
13. Liu YY, Stokkel MP, Morreau HA, Pereira AM, Romijn JA, Smit JWA. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin Endocr 2008;68:605-9.
14. Kersten S, Desvergne B, Wahli W. Roles of PPARS in health and disease. Nature 2000;405;421-4.
15. Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 2005;12:291-303.
16. Martelli ML, Iuliano R, Pera I, Samà I, Monaco C, Cammarota S et al. Inhibitory effects of peroxisome proliferators-activated receptor gamma on thyroid cancer growth. J Clin Endocrinol Metab 2002;87:4728-35.
17. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-6.
18. Clinical trials.gov [Homepage]. [cited 2009 October 7]. Available at: www.clinicaltrial.gov
19. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferators-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000;92:418-23.
20. De Ruiiter AJ, van Gennip AH, Caron HN, Kemp S, van kuilenburg AB. Histone deacetylases (HDACs) characterization of the classical HDAC family. Biochem J 2003;370:737-49.
21. Milano A, Chiofalo MG, Basile M, Salzano de Luna A, Pezzullo L, Caponigro F. New molecular targeted therapies in thyroid cancer. Anti-Cancer Drugs 2006;17:869-79.
22. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13:477-83.
23. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G. Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells: J Clin Endocrinol Metab2004;89:1006-9.
24. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon Vm et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999;59:4392-9.
25. Kelly WK, O'Connor O, Krug LM, Chiao JH, Heaney M, Curley T et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Clin Cancer Res 2003;9:3578-88.
26. Shen WT, Chung WY. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferators-activated receptor-gamma agonists. Thyroid 2005;15:594-7.
27. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T et al. Epigenetic silencing of TTF1/NKX2-1 through DANN hypermethylation and histone H3 modulation in thyroid carcinomas Lab Investig 2009;89:791-9.
28. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB et al. Methylation of TSH receptor gene in epithelial thyroid tumors:a marker of malignancy and a cause of gene silencing. Cancer Res 2003;63:2316-21.
29. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide in the treatment of acute promyelocitic leukaemia. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
30. Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002:14-9.
31. Frolich E, Czarnocka B, Brossart P, Wahl R. Antitumor effects of arsenic trioxide in transformed human thyroid cells. Thyroid 2008;18:1183-92.